Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
Titel:
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
Auteur:
Kersting, Sabina Dubois, Julie Nasserinejad, Kazem Dobber, Johan A Mellink, Clemens van der Kevie-Kersemaekers, Anne-Marie F Evers, Ludo M de Boer, Fransien Koene, Harry R Schreurs, John van der Klift, Marjolein Velders, Gerjo A van der Spek, Ellen van der Straaten, Hanneke M Hoogendoorn, Mels van Gelder, Michel Posthuma, Eduardus F M Visser, Hein P J Houtenbos, Ilse Idink, Cecile A M Issa, Djamila E Dompeling, Ellen C van Zaanen, Henk C T Veelken, Hendrik Levenga, Henriette Tick, Lidwine W Terpstra, Wim E Tonino, Sanne H Boyer, Michelle Mobasher, Mehrdad Levin, Mark-David Kater, Arnon P